You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 3.236.0.0/16 has been blocked (disabled) by ‪ST47‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider. To prevent abuse, web hosts may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a web host's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and they should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 06:21, 30 September 2026.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪Jon Kolbert‬. The reason given is Open proxy/Webhost: See the help page if you are affected .
- Start of block: 05:35, 21 February 2024
- Expiry of block: 05:35, 21 February 2029
Your current IP address is 3.236.201.96. The blocked range is 3.236.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

((More citations needed|date=December 2007))
[[File:LNCaP.jpg|thumb|Representative phase-contrast image of LNCaP cells. Scale bars represent 100µm.]]
[[File:Comparison of cancer cell lines.png|thumb|Properties of common PCa cell lines]]
'''LNCaP''' cells are a [[cell line]] of human cells commonly used in the field of [[oncology]].  LNCaP cells are [[androgen]]-sensitive human [[prostate]] [[adenocarcinoma]] cells derived from the left supraclavicular lymph node [[metastasis]] from a 50-year-old caucasian male in 1977.  They are adherent epithelial cells growing in aggregates and as single cells.<ref name="pmid6831420">((cite journal |vauthors=Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP | title = LNCaP model of human prostatic carcinoma | journal = Cancer Res | volume = 43 | issue = 4 | pages = 1809–18 |date=April 1983 | pmid = 6831420 ))</ref>

One major obstacle to conducting the most clinically relevant [[prostate cancer]] (PCa) research has been the lack of cell lines that closely mimic human disease progression.<ref name="pmid8168083" /> Two hallmarks of metastatic human prostate cancer include the shift of aggressive PCa from androgen-sensitivity to an Androgen Insensitive (AI) state, and the propensity of PCa to metastasize to bone.<ref>((cite web|last1=Fanelli|first1=Alex|title=LNCaP Cell Line: human prostate adenocarcinoma cell line|date=2016|url=http://www.lncap.com/|access-date=3 December 2017))</ref> Although the generation of AI cell lines has been quite successful as  demonstrated in the “classic” cell lines [[DU145]] and [[PC3]], the behavior of these cells in bone does not fully mimic clinical human disease. It is well established that human PCa [[bone metastasis]] form osteoblastic lesions rather than osteolytic lesions seen in other cancers like breast cancer.<ref name="pmid10344214">((cite journal |vauthors=Koeneman KS, Yeung F, Chung LW | title = Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment | journal = Prostate | volume = 39 | issue = 4 | pages = 246–61 |date=June 1999 | pmid = 10344214 | doi = 10.1002/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U | doi-access = free ))</ref><ref name="pmid11351351">((cite journal |vauthors=Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET | title = Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro | journal = Prostate | volume = 47 | issue = 3 | pages = 212–21 |date=May 2001 | pmid = 11351351 | doi = 10.1002/pros.1065 | hdl = 2027.42/34759 | s2cid = 31076493 | url = https://deepblue.lib.umich.edu/bitstream/2027.42/34759/1/1065_ftp.pdf | hdl-access = free ))</ref> Similarly, PC-3 and DU145 cells form osteolytic tumors. To develop an AI-PCa cell model that more closely mimics clinical disease, LNCaP sublines have been generated to provide the most clinically relevant tissue culture tools to date.

==History==

The LNCaP ('''L'''ymph '''N'''ode '''Ca'''rcinoma of the '''P'''rostate) [[cell line]] was established from a metastatic lesion of human prostatic adenocarcinoma. The LNCaP cells grow readily in vitro (up to 8 x 10<sup>5</sup> cells/sq cm; doubling time, 60 hr), form clones and are highly resistant to human fibroblast [[interferon]].<ref name="pmid6831420" /> LNCaP cells have a modal chromosome number of 76 to 91, indicative of a human male karyotype with several marker [[chromosome]]s.<ref name="pmid6831420" /> The malignant properties of LNCaP cells are maintained in athymic nude mice which develop tumors at the injection site and show a similar doubling time ''in vivo''.<ref name="pmid6831420" />

High-affinity specific [[androgen]] and [[estrogen]] receptors are present in the cytosol and nuclear fractions.<ref name="pmid6831420" /> The LNCaP line is [[hormone|hormonally]] responsive, shown by ''in vitro'' 5 alpha-dihydrotestosterone modulation of cell growth and acid phosphatase production.<ref name="pmid6831420" /> LNCaP cells also express [[Prostate Specific Antigen]] (PSA).<ref name="pmid6831420" /> ''In vivo'', Male mice develop tumors earlier and at a greater frequency than do females and hormonal manipulations show that the frequency of tumor development correlates with serum androgen levels.<ref name="pmid6831420" /> The rate of the tumor growth, however, is independent of the gender or hormonal status of the host.<ref name="pmid6831420" />

==C4/C5 and C4-2==
<!-- Deleted image removed: [[File:Thalmann figure.png|thumb|Generation of LNCaP sublines.<ref name="pmid8168083">((cite journal |vauthors=Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW | title = Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer | journal = Cancer Res | volume = 54 | issue = 10 | pages = 2577–81 |date=May 1994 | pmid = 8168083 ))</ref>
]] -->
Wu et al. (1994) reproduced the human-derived LNCaP tumors in immunocompromised mice by co-injection of LNCaP cells with MS human bone fibroblasts.<ref name="pmid8169003">((cite journal |vauthors=Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW | title = Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells | journal = Int J Cancer | volume = 57 | issue = 3 | pages = 406–12 |date=May 1994 | pmid = 8169003 | doi = 10.1002/ijc.2910570319| s2cid = 22056818 ))</ref> Cells were subcutaneously injected at multiple sites into the mouse flank and after approximately 4 weeks of growth, tumors were easily detectable by physical examination and had a high rate of growth (17-33 mm3/day).<ref name="pmid8169003"/>

To replicate the hallmark shift of PCa cells to AI, LNCaP host mice were castrated by way of midscrotal incision at approximately 8 weeks post injection. Tumors were maintained in castrated hosts for 4 to 5 weeks at which time remaining tumors were harvested. In total, two subsets of cells were collected from castrated hosts: C4 and C5, collected at 4 and 5 weeks respectively.<ref name="pmid8169003"/>

To further select for AI-PCa cells, the C4 subline was co-injected with MS human fibroblasts into a castrated host. The resulting tumors were isolated and an additional subline was generated, C4-2.<ref name="pmid8169003"/>

'''[[Karyotype]] comparisons''' indicate that
LNCaP cells grown in intact hosts (M subline) have a modal chromosomal distribution number of 83,  C4 and C5 sublines with 85, and the C4-2 subline with 83.<ref name="pmid8169003"/>

To further verify that these cells were of human origin karyotype analysis determined that the parental LNCaP cells had 7 distinct marker chromosomes, with two copies of each. The M, C4, C5, and C4-2 sublines contained most of the marker chromosomes, with the M subline being most similar to the parental LNCaP cells. C4, C5 and C4-2 are only minutely distinct from LNCaP and the M subline with the addition of a marker chromosome resulting from a segment addition to chromosome 6. A [[Y chromosome]] is not present in most C4, C5 and C4-2 cells, suggesting major chromosomal alterations.<ref name="pmid8169003"/>

C4, C5, and C4-2 sublines grow well under identical tissue culture conditions as LNCaP with similar growth rates. Parental LNCaP, M, C4, and C5 subline have similar baseline gene expression levels of [[ornithine decarboxylase]] (ODC) and [[Prostate Specific Antigen]] (PSA) however, M, C4, and C5 sublines express 5-10X more PSA mRNA. M, C4, C5 and C4-2 also expressed reduced human [[androgen receptor]] mRNA as expected in AI cells.<ref name="pmid8169003"/>

'''Androgen Insensitivity'''
All sublines were treated with [[dihydrotestosterone]] (DHT), a high-affinity ligand for AR. DHT treatment elicited markedly reduced growth in C4 and C5 cells and no growth in C4-2 cells when compared to the high rate of growth seen in LNCaP cells, suggesting reduced androgen sensitivity in C4 and C5 and AI in C4-2 cells. Whole-cell AR assay also indicated that LNCaP cells have a much higher affinity form of AR (Kd = 159 pM) when compared to C4-2 (Kd = 267 pM).<ref name="pmid8169003"/>

'''Tumorigenicity'''
C4 and C5 sublines exhibit greatly increased tumorigenicity when injected in intact male mice, unlike parental LNCaP cells. C4 and C5 were also able to form highly vascularized carcinomas in castrated mice when co-injected with MS human fibroblasts. The C4-2 subline more readily forms tumors in intact hosts than C4 and C5 sublines and they are the only cells able to form tumors in castrated host without co-injection of MS human bone fibroblasts. These same C4-2 tumors stained for PSA and secreted high levels of PSA into the growth medium.<ref name="pmid8169003"/>

==C4-2B==
To generate a bone metastatic subline, C4-2 cells were orthotopically injected into castrated male mice. These cells formed large primary tumors of the prostate, lymph nodes, as well as osseus tumors. Isolation of these osseus tumors resulted in the C4-2B subline.
C4-2B cells were positive for PSA and [[cytokeratin 8]], confirming their prostatic origin. Most importantly, immunohistochemical staining of the C4-2B tumors were positive for osteoblast activity suggesting the induction of osteoblastic tumor formation mirroring the progression of human PCa.<ref name="pmid8168083">((cite journal |vauthors=Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW | title = Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer | journal = Cancer Res | volume = 54 | issue = 10 | pages = 2577–81 |date=May 1994 | pmid = 8168083 ))</ref>

When cultured in a “promineralization medium” that contains [[ascorbic acid]] (known to promote skeletal-like ECM formation in osteoblasts) and a source of phosphate (for [[hydroxyapatite]] formation), C4-2B cells produce and retain approximately 8x more mineralized calcium than parental LNCaP cells. C4-2B cells also express higher levels of [[osteoprotegerin]] (OPG), [[alkaline phosphatase]], [[bone sialoprotein]] (BSP), [[Osteocalcin]] (OCN), [[RANKL]], and [[Osteonectin]] (OSN) mRNA, all of which are highly expressed by [[osteoblasts]].
Osteoblast promoter activity is also higher in C4-2B cells when compared to LNCaP, as indicated by [[Cbfa1]] transcription factor expression. Concomitantly, [[BMP7]], a known inducer of Cbfa1, is also more highly expressed in C4-2B cells, further suggesting many osteoblast-like properties.<ref name="pmid11351351"/>

== Androgen Independent Variants ==

'''LN95''' cells were derived from LNCaP cultured in RPMI-1640 (without phenol red) with 10% charcoal stripped fetal bovine serum.<ref name="ReferenceA">((cite journal|last1=Pflug|first1=BR|last2=Reiter|first2=RE|last3=Nelson|first3=JB|title=Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines.|journal=The Prostate|date=1 September 1999|volume=40|issue=4|pages=269–73|pmid=10420156|doi=10.1002/(sici)1097-0045(19990901)40:4<269::aid-pros9>3.0.co;2-6|s2cid=19432542 ))</ref> LN95 cells differ from parental LNCaP cells morphologically, with pronounced dendritic extensions, and molecularly, with [[Androgen receptor]] variant expression similar to that of AR-V7<sup>High</sup> [[VCaP]] cells.<ref name="ReferenceB">((cite journal|last1=Liu|first1=LL|last2=Xie|first2=N|last3=Sun|first3=S|last4=Plymate|first4=S|last5=Mostaghel|first5=E|last6=Dong|first6=X|title=Mechanisms of the androgen receptor splicing in prostate cancer cells.|journal=Oncogene|date=12 June 2014|volume=33|issue=24|pages=3140–50|doi=10.1038/onc.2013.284|pmid=23851510|pmc=4553036))</ref> Notably, LN95 cells are significantly more tumour initiating than their parental counterparts ''in vivo''.<ref name="ReferenceA"/>

'''LNCaP-AI''' (or LN-AI) cells were derived from 6-Month culture of LNCaP parental cells in charcoal stripped serum.<ref name="ReferenceC">((cite journal|last1=Lu|first1=S|last2=Tsai|first2=SY|author3-link=Ming-Jer Tsai|last3=Tsai|first3=MJ|title=Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells.|journal=Endocrinology|date=November 1999|volume=140|issue=11|pages=5054–9|doi=10.1210/endo.140.11.7086|pmid=10537131|doi-access=free))</ref> While LNCaP-AI are wholly androgen independent, they retain high expression of [[Androgen receptor]], low expression of AR-V7, and remain androgen responsive.<ref name="ReferenceB"/> The mechanism of the highly proliferative phenotype of LNCaP-AI cells appears to be loss of cell cycle regulator expression (p21, p16) and increased anti-apoptotic [[Bcl2]] expression.<ref name="ReferenceC"/><ref>((cite journal|last1=Sampson|first1=N|last2=Neuwirt|first2=H|last3=Puhr|first3=M|last4=Klocker|first4=H|last5=Eder|first5=IE|title=In vitro model systems to study androgen receptor signaling in prostate cancer.|journal=Endocrine-Related Cancer|date=April 2013|volume=20|issue=2|pages=R49–64|doi=10.1530/ERC-12-0401|pmid=23447570|doi-access=free))</ref>

== References ==
((Reflist | 2))

==Further reading==
* ((cite journal  |vauthors=Li H, Lovci MT, Kwon YS, Rosenfeld MG, Fu XD, Yeo GW |title=Determination of tag density required for digital transcriptome analysis: application to an androgen-sensitive prostate cancer model |journal=Proc Natl Acad Sci USA |volume=105 |issue= 51 |pages= 20179–84 |year= 2008 |pmid= 19088194  | doi=10.1073/pnas.0807121105  | pmc=2603435 |bibcode=2008PNAS..10520179L |doi-access=free ))


==External links==
* [http://cell-lines.toku-e.com/Cell-Lines_3599.html Transfection data on LNCaP Cells]
* [https://www.cellosaurus.org/CVCL_0395 Cellosaurus entry for LNCaP]
* [https://www.cellosaurus.org/CVCL_4783 Cellosaurus entry for C4]
* [https://www.cellosaurus.org/CVCL_4782 Cellosaurus entry for C4-2]
* [https://www.cellosaurus.org/CVCL_4784 Cellosaurus entry for C4-2B]
* [https://www.cellosaurus.org/CVCL_M132 Cellosaurus entry for C5]

((DEFAULTSORT:Lncap))
[[Category:Human cell lines]]
[[Category:Cancer research]]
[[Category:Prostate cancer]]

Pages transcluded onto the current version of this page (help):

LNCaP (edit)
Template:Ambox (view source) (template editor protected)
Template:Cite journal (view source) (protected)
Template:Cite web (view source) (protected)
Template:Find sources mainspace (view source) (template editor protected)
Template:Main other (view source) (protected)
Template:More citations needed (view source) (template editor protected)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Module:Arguments (view source) (protected)
Module:Category handler (view source) (protected)
Module:Category handler/blacklist (view source) (protected)
Module:Category handler/config (view source) (protected)
Module:Category handler/data (view source) (protected)
Module:Category handler/shared (view source) (protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Find sources (view source) (template editor protected)
Module:Find sources/config (view source) (template editor protected)
Module:Find sources/links (view source) (template editor protected)
Module:Find sources/templates/Find sources mainspace (view source) (template editor protected)
Module:Message box (view source) (protected)
Module:Message box/ambox.css (view source) (protected)
Module:Message box/configuration (view source) (protected)
Module:Namespace detect/config (view source) (protected)
Module:Namespace detect/data (view source) (protected)
Module:Unsubst (view source) (protected)
Module:Yesno (view source) (protected)

Return to LNCaP.

Retrieved from "https://en.wikipedia.org/wiki/LNCaP"